Advanced Solid Tumors
Advanced Solid Tumors
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
20
Clinical Trials
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05853367 / MK0472-001
A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors.
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT05067283 / MK1084-001
A phase I, open-label, multicenter study to assess safety, tolerability, PK and efficacy of MK-1084 as monotherapy and in combination with pembrolizumab in subjects with KRASG12C mutant advanced solid tumors
Learn More
Advanced Solid Tumors
Phase II/III
Enrolling
nct/study# NCT05533697 / MRNA-4359-P101
Phase I/II clinical study of mRNA-4359 Administered Alone or in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors.
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06586957 / NKT3964-101
A PHASE 1, FIRST-IN-human, open-label study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of the novel oral CDK2 DEGRADER NKT3964 in adults with advanced/metastatic solid tumors
Learn More
Advanced Solid Tumors
Phase I
Enrolling
nct/study# NCT06792552 / SIM0505-101
A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS
Learn More
Advanced Solid Tumors
Phase I/II
Enrolling
nct/study# NCT05584670 / TCD17620
A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy in adults with advanced solid tumors
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.